Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

Marie Skłodowska-Curie Action · Running

StopKidneyCachexia Contribution of adipose tissue and liver to cachexia associated with chronic kidney disease

Coordinator
Institut National De La Sante Et De La Recherche Medicale, France
Runs
3 November 2025 to 2 November 2027
Status
Running
EU funding
€242k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101202047

What the project is doing

In the project's own words, from its summary on CORDIS.

Cachexia is a life-threatening wasting syndrome, defined by an involuntary loss of body weight, that affects a large proportion of patients with advanced chronic diseases. Kidney diseases affect > 850 million people worldwide and represent the 10th leading cause of death. In this context, cachexia associated with chronic kidney diseases (KCx) is a huge burden in end-stage patients with kidney replacement therapies. Patients with KCx experience frailty, which worsens their quality of life (impacting their social- and professional life), hospitalization and mortality rates.

So far, most research efforts have tried to identify primary pro-cachectic factors contributing to muscle wasting, but this was unfruitful in terms of therapeutics. Here, we are proposing a translational and interdisciplinary project that will focus on novel tissues (i.e adipose tissue and liver) with great relevance in the control of systemic energy metabolism. Preliminary data obtained in collaboration with the host laboratory have shown that these two tissues undergo a strong remodeling of their glucose and lipid metabolism, which could contribute to energy loss and body wasting.

The main objectives of the project will be: 1) to understand the mechanisms by which altered metabolic pathways contribute to wasting in fat, liver and muscle cells; 2) to assess the biomarker potential of products of these metabolic pathways for early diagnosis of patients with KCx; and 3) to assess the therapeutic potential of targeting these metabolic pathways in mouse models of KCx. With this project, we will develop a novel research axis combining my expertise in the field of cachexia and metabolism to the expertise of the host in the field of kidney diseases.

The project will be supported by highly relevant in vitro and in vivo models, access to patients’ samples, and innovative techniques. This fellowship will allow to develop my independency and to get a competitive research profile to pursue an academic career.

Topics

Who is involved

OrganisationCityCountryRole
Institut National De La Sante Et De La Recherche MedicaleParisFranceCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI